Active, not recruitingPhase 2NCT02873962

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

Studying Malignant epithelial tumor of ovary

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Dana-Farber Cancer Institute
Principal Investigator
Joyce Liu, MD MPH
Dana-Farber Cancer Institute
Intervention
Bevacizumab(drug)
Enrollment
72 enrolled
Eligibility
18 years · FEMALE
Timeline
20162027

Study locations (3)

Collaborators

Bristol-Myers Squibb · Clovis Oncology, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02873962 on ClinicalTrials.gov

Other trials for Malignant epithelial tumor of ovary

Additional recruiting or active studies for the same condition.

See all trials for Malignant epithelial tumor of ovary

← Back to all trials